A Randomized, Controlled, Double-blind, Multicenter Phase III Clinical Study of Envafolimab Plus Platinum-based Doublet Chemotherapy Versus Placebo Plus Platinum-based Doublet Chemotherapy in Patients With Non-small Cell Lung Cancer is a PHASE3 clinical asset sponsored by 3D Medicines (Sichuan) Co., Ltd. in Non-small Cell Lung Cancer. SEO and diligence focus: Envalfolimab subcutaneously injected+Platinum-based doublet chemotherapy intravenous injection, placebo subcutaneously injected +Platinum-based doublet chemotherapy intravenous injection, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.